Warnings and Precautions Central Nervous System Depression in patients with succinic semialdehyde dehydrogenase deficiency.in combination with sedative hypnotics or alcohol and.Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.īecause of the risks of CNS depression and abuse and misuse, XYWAV is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS. Abuse and MisuseThe active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB).Many patients who received XYWAV during clinical trials in narcolepsy and idiopathic hypersomnia were receiving CNS stimulants. Clinically significant respiratory depression and obtundation may occur in patients treated with XYWAV at recommended doses. Central Nervous System DepressionXYWAV is a CNS depressant.WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE. Medications for daytime sleepiness in individuals with idiopathic hypersomnia. Trotti LM, Becker LA, Friederich Murray C, Hoque R.Palo Alto, CA: Jazz Pharmaceuticals, Inc. XYWAV ® (calcium, magnesium, potassium, and sodium oxybates).

Centers for Medicare & Medicaid Services website. ICD-10-CM tabular list of diseases and injuries.Subjective symptoms in idiopathic hypersomnia: beyond excessive sleepiness. Vernet C, Leu-Semenescu S, Buzare MA, Arnulf I.Disease symptomatology and response to treatment in people with idiopathic hypersomnia: initial data from the Hypersomnia Foundation registry. Trotti LM, Ong JC, Plante DT, Murray CF, King R, Bliwise DL.Precision medicine for idiopathic hypersomnia. Darien, IL: American Academy of Sleep Medicine 2014. International Classification of Sleep Disorders.

Xyrem cataplexy